Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers

Official Title

A Phase 1/1b, Open-Label, Multicentre, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers

Summary:

This is a phase 1/1b open-label, multicentre, dose-selection study of CPI-444, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumour activity of CPI-444 as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumours. CPI-444 blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumour activity of T cells and other immune cells.

Trial Description

Primary Outcome:

  • Incidence of dose-limiting toxicities (DLTs) of CPI-444 as a single agent and in combination with atezolizumab
  • Objective response rate per RECIST v1.1 criteria of CPI-444 as a single agent and in combination with atezolizumab
  • Incidence of treatment-emergent adverse events, as assessed by NCI CTCAE v.4.03, of CPI-444 as a single agent and in combination with atezolizumab
  • Mean and median Area under the curve (AUC) of CPI-444
  • Mean and median Maximum concentration (Cmax) of CPI-444
This is a phase 1/1b open-label, multicentre, dose-selection study of CPI-444, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumour activity of CPI-444 as a single agent and in combination with atezolizumab, an intravenous PD-L1 inhibitor. CPI-444 blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumour activity of T cells and other immune cells.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society